Frontiers in pharmacologyOct 8, 2026

Using gene function data to identify MED12 as a potential RNA-targeting weakness in acute myeloid leukemia and testing a targeted siRNA delivery method

mRNA Technology Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Oct 9, 2026

Abstract

Acute myeloid leukemia (AML) relies on complex transcriptional and epigenetic programs that are challenging to target.

Conventional small molecules may struggle to effectively target the underlying mechanisms of AML.
RNA interference could offer a way to disrupt these critical vulnerabilities in AML.
Target selection and delivering siRNA into cells are significant challenges that need to be addressed.

Simplified

Acute myeloid leukemia (AML) depends in part on transcriptional and epigenetic programs that can be difficult to target with conventional small molecules. RNA interference provides a potential approach to perturb such vulnerabilities, but target selection and intracellular siRNA delivery remain major challenges.

Full Text

Full text is available at the source.

View Full Text ↗

Using gene function data to identify MED12 as a potential RNA-targeting weakness in acute myeloid leukemia and testing a targeted siRNA delivery method

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the mrna technology brief